Study Type: Preclinical
Related Omni-Biotic Formulation: AB 10

• Antifungal Activity
• Antibacterial Activity
• Gut Microbiome Supportive

Study Type: pilot study
Related Omni-Biotic Formulation: AB 10

• <58% reduction in multidrug resistant gram negative infection (stool)
• <72% reduction in multidrug resistant gram negative infection (skin)
• Demonstrated safety and efficacy in long term care facilities

Study Type: participatory evaluation
Related Omni-Biotic Formulation: AB 10

• 16% reduction in antibiotic associated diarrhea
• Demonstrated safety and efficacy in nursing homes

Study Type: pilot study
Related Omni-Biotic Formulation: AB 10

• Complete resolution of Clostridium difficile infection

Study Type: observational study
Related Omni-Biotic Formulation: AB 10

This observational study demonstrated the successful use of Omni-Biotic AB 10 (AAD) for primary prevention of antibiotic associated diarrhea in post surgical patients.

Study Type: review article
Related Omni-Biotic Formulation: AB 10

This systematic review and meta-analysis evaluated the efficacy of co-administration of probiotics with antibiotics. Findings demonstrated that probiotics used concurrently with antibiotics reduce the risk of antibiotic associated diarrhea and C. difficile infection.

Study Type: pilot clinical
Related Omni-Biotic Formulation: Stress Release

• Reduction in psoriatic arthritis disease activity
• Reduced in fecal zonulin (marker of intestinal permeability)
• Reduced fecal calprotectin (marker of intestinal inflammation)

Study Type: double blind, randomized controlled trial
Related Omni-Biotic Formulation: Stress Release

• Decreased functional connectivity in default mode, middle and superior frontal gyrus networks
• Increased functional connectivity in salience network (cingulate gyrus and precuneus cortex)
• Brain activity shift indicative of less connectivity associated with ruminative thought and more connectivity associated with executive function

Study Type: double blind, randomized controlled trial
Related Omni-Biotic Formulation: Stress Release

• Improved positive affect and cognitive reactivity
• Improved memory performance
• Improved gut microbiome diversity

Study Type: observational trial
Related Omni-Biotic Formulation: Stress Release

• Increased gut microbiome diversity and short chain fatty acid production
• Reduced inflammatory CD4+ T cells and fecal zonulin levels
• Decreased IBS disease severity

Study Type: review article
Related Omni-Biotic Formulation: Stress Release

This review summarizes the available evidence describing the bi-directional gut-brain relationship including neural, endocrine, immune, and humoral pathways. It also explores relevant pathophysiological mechanisms.

Study Type: review article
Related Omni-Biotic Formulation: Stress Release

This review highlights the evidence supporting the connection between stress and the gut microbiota, with specific focus on the mechanisms by which the microbiota impacts stress response, behavior, and visceral pain.

Study Type: review article
Related Omni-Biotic Formulation: Balance

This review explores the roles the microbiome plays in the development and function of the immune system.

Study Type: review article
Related Omni-Biotic Formulation: Balance

This review discusses the relationship between the gut microbiome and immunity highlighting the influence of modern diet, pharmaceuticals and hygiene on rising rates of inflammatory and autoimmune disorders.

Study Type: double blind, randomized controlled trial
Related Omni-Biotic Formulation: Hetox

• Increased neutrophil resting burst and neopterin levels 
• Improvement in liver function
• Demonstrated safety and efficacy in stable liver cirrhosis

Study Type: double blind, randomized controlled trial
Related Omni-Biotic Formulation: Hetox

• Reduced abdominal adiposity (hip:waist ratio)
• Improved HOMA-IR
• Demonstrated safety and efficacy in medication naive T2DM

Study Type: double blind, randomized controlled trial
Related Omni-Biotic Formulation: Hetox

• Reduced circulating endotoxin levels (70%)
• Reduced metabolic markers: glucose (38%), insulin (38%), HOMA-IR (64%), triglycerides (48%), total cholesterol (19%), total/HDL-cholesterol ratio (19%)
• Reduced inflammatory markers: TNF-α (67%), IL-6 (77%), CRP (53%), resistin (53%)

Study Type: review article
Related Omni-Biotic Formulation: Hetox

This review discusses gut-liver communications in various forms of liver disease and the potential to use the microbiome to determine the stage of liver disease as well as predicting the effects of dietary and pharmaceutical interventions.

Study Type: preclinical analysis
Related Omni-Biotic Formulation: PandA

• Decreased Th2 cytokine production
• Diversion of immune system into regulatory/tolerant mode

Study Type: preclinical analysis
Related Omni-Biotic Formulation: PandA

• Skewed neonatal naive T Cells toward Th1
• Up-regulation of co-stimulatory molecules
• No skewing toward Th2

Study Type: double blind, randomized controlled trial
Related Omni-Biotic Formulation: PandA

• Decreased in vitro production of IL-5
• Increased Lc. lactis colonization
• Reduced incidence of eczema in high-risk children

Study Type: double blind, randomized controlled trial: follow-on
Related Omni-Biotic Formulation: PandA

• Increased short chain fatty acid and lactate production
• Decreased lactose and succinate levels
• Demonatrated safety and efficacy in children at risk to develop eczema

Study Type: review article
Related Omni-Biotic Formulation: PandA

This meta analysis found that probiotics have a protective role in atopic dermatitis (eczema) prevention when administered during the pre- and post-natal period.